Investors News Releases News Releases Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Annual Reports News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Aug 05 2020 Cyclacel Pharmaceuticals to Release Second Quarter 2020 Financial Results Jul 13 2020 Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer May 12 2020 Cyclacel Pharmaceuticals Reports First Quarter 2020 Financial Results May 05 2020 Cyclacel Pharmaceuticals to Release First Quarter 2020 Financial Results Apr 24 2020 Cyclacel Announces Closing of $20 Million Public Offering Apr 21 2020 CYCLACEL ANNOUNCES PRICING OF $20 MILLION PUBLIC OFFERING Apr 20 2020 Cyclacel Pharmaceuticals Announces Collaboration With the University of Edinburgh to Study Its CDK Inhibitors to Reduce Runaway Inflammation in COVID-19 Disease Apr 14 2020 Cyclacel Announces Reverse Stock Split Feb 26 2020 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results Feb 19 2020 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results Feb 03 2020 Cyclacel Pharmaceuticals to Present at the 2020 BIO CEO & Investor Conference Jan 13 2020 Cyclacel Pharmaceuticals Reviews 2019 Achievements and Announces Key Business Objectives for 2020 Jan 06 2020 Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2020 in San Francisco Dec 09 2019 Cyclacel’s CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias Nov 13 2019 Cyclacel Pharmaceuticals Reports Third Quarter 2019 Financial Results Nov 07 2019 Cyclacel Pharmaceuticals to Release Third Quarter 2019 Financial Results Nov 06 2019 Cyclacel Pharmaceuticals Announces Multiple Clinical Abstracts Selected for Presentation at the ASH 2019 Annual Meeting Sep 23 2019 Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference Sep 09 2019 Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid Tumors Sep 04 2019 Cyclacel Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference Aug 13 2019 Cyclacel Pharmaceuticals Reports Second Quarter 2019 Financial Results Aug 07 2019 Cyclacel Pharmaceuticals to Release Second Quarter 2019 Financial Results Jul 22 2019 Cyclacel Pharmaceuticals Announces First Patient Treated in a Phase 1/2 Study of Sapacitabine and Venetoclax in Relapsed or Refractory AML or MDS Patients May 14 2019 Cyclacel Pharmaceuticals Reports First Quarter 2019 Financial Results May 08 2019 Cyclacel Pharmaceuticals to Release First Quarter 2019 Financial Results Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Toolkit Email AlertsRSS FeedsPrint Page
News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Aug 05 2020 Cyclacel Pharmaceuticals to Release Second Quarter 2020 Financial Results Jul 13 2020 Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer May 12 2020 Cyclacel Pharmaceuticals Reports First Quarter 2020 Financial Results May 05 2020 Cyclacel Pharmaceuticals to Release First Quarter 2020 Financial Results Apr 24 2020 Cyclacel Announces Closing of $20 Million Public Offering Apr 21 2020 CYCLACEL ANNOUNCES PRICING OF $20 MILLION PUBLIC OFFERING Apr 20 2020 Cyclacel Pharmaceuticals Announces Collaboration With the University of Edinburgh to Study Its CDK Inhibitors to Reduce Runaway Inflammation in COVID-19 Disease Apr 14 2020 Cyclacel Announces Reverse Stock Split Feb 26 2020 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results Feb 19 2020 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results Feb 03 2020 Cyclacel Pharmaceuticals to Present at the 2020 BIO CEO & Investor Conference Jan 13 2020 Cyclacel Pharmaceuticals Reviews 2019 Achievements and Announces Key Business Objectives for 2020 Jan 06 2020 Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2020 in San Francisco Dec 09 2019 Cyclacel’s CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias Nov 13 2019 Cyclacel Pharmaceuticals Reports Third Quarter 2019 Financial Results Nov 07 2019 Cyclacel Pharmaceuticals to Release Third Quarter 2019 Financial Results Nov 06 2019 Cyclacel Pharmaceuticals Announces Multiple Clinical Abstracts Selected for Presentation at the ASH 2019 Annual Meeting Sep 23 2019 Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference Sep 09 2019 Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid Tumors Sep 04 2019 Cyclacel Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference Aug 13 2019 Cyclacel Pharmaceuticals Reports Second Quarter 2019 Financial Results Aug 07 2019 Cyclacel Pharmaceuticals to Release Second Quarter 2019 Financial Results Jul 22 2019 Cyclacel Pharmaceuticals Announces First Patient Treated in a Phase 1/2 Study of Sapacitabine and Venetoclax in Relapsed or Refractory AML or MDS Patients May 14 2019 Cyclacel Pharmaceuticals Reports First Quarter 2019 Financial Results May 08 2019 Cyclacel Pharmaceuticals to Release First Quarter 2019 Financial Results Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
Jul 13 2020 Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer
Apr 20 2020 Cyclacel Pharmaceuticals Announces Collaboration With the University of Edinburgh to Study Its CDK Inhibitors to Reduce Runaway Inflammation in COVID-19 Disease
Jan 13 2020 Cyclacel Pharmaceuticals Reviews 2019 Achievements and Announces Key Business Objectives for 2020
Dec 09 2019 Cyclacel’s CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias
Nov 06 2019 Cyclacel Pharmaceuticals Announces Multiple Clinical Abstracts Selected for Presentation at the ASH 2019 Annual Meeting
Sep 09 2019 Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid Tumors
Sep 04 2019 Cyclacel Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference
Jul 22 2019 Cyclacel Pharmaceuticals Announces First Patient Treated in a Phase 1/2 Study of Sapacitabine and Venetoclax in Relapsed or Refractory AML or MDS Patients
